XX% CytoSorb the record and COVID-XX good you outstanding had of $XX.X XXXX million of Thank backdrop versus XXXX $XX.X XXXX. a in we We million much, afternoon, everyone. increase. an Amy Despite announced sales very
year a record announced product $X.X increase. XXXX versus ago, XX% also million million of QX sales $XX.X a We
delivered had year. CytoSorb XX% a which with debt. $XX.X year long-term quarter, from were of the across cumulative of XX,XXX blended million we and XX% to Our no date, And distribution solid fourth with as the than countries. in product more XXX,XXX in XX ago, year, sheet was record for the up a cash XX% cartridges We and gross margins end balance the
X,XXX In treated including States breakthrough of removal are emergent more cardiothoracic ticagrelor patients for we FDA to this in addition, we granted FDA also more in granted here rivaroxaban than and XX EU remove XXXX. COVID-XX the received emergencies the And countries, We than authorization under application. for United ticagrelor in approval surgery. designation during
received solid universal new inflammatory ECOS-XXXCY We for DoD approval complete Union awarded our $X.X vivo also European for product organs well perfusion ex enable that development plasma preclinical HemoDefend-BGA remove during will contracts we And whole of as also to were transplants. the cartridge million as in organ transfusions. called from toxins to blood
number One strategy and strong we that current topics for sales to a with coupled of we're CytoSorb, today performance new to wanted financial cover our and cash key of solid demand growth. With our in position initiatives drive anticipated the solid the executing normal. is growth
in $XXX approval and peak U.S. the anticipation potential remains our profitability. capacity we the to where in clinical of of accommodate a of and cardiothoracic removal commercialization strategy growth million manufacturing pre-COVID-XX achieving a revenue solid surgery, million ticagrelor of driving United Europe, new our on in sales, will and on prioritizing be States in to on to return U.S. based to $XXX to is building growth approval to our expand begin also execute in out facility in the team GAAP replacing path it to U.S. First, our CytoSorb opportunity while what is it strategy, sales, COVID-XX maximize focused then COVID-XX product regulatory
that For bullets. four are last today's bullets discussion, out, the will on we given first the further three focus
variants. COVID the the talk by corner red revenue, story. weeks let's COVID-XX graph. is have can have cases of seen in What weeks States, has darker last can that we resurgence may many plateaued see, contribute COVID, it's you United to expected of half a hand because about worldwide the as the the decline, well in of COVID-XX particularly of this the darker be first Latin worldwide. see still been After year. Europe, the and as few countries, of In right to America, of believe as particularly similar from status virus a in We lower First, in as you
However, quite down see as gone can you dramatically. here, COVID-XX has
significant the vaccine cases XXXX. a And significant which of And heat graph, less of is see represented you also plateauing in deaths been decline per since in new daily X,XXX to cases, has away in number of know. what now of with decline upper States cases. positive by cases And actually the begin side the than was December decrease also can the we the the the March weeks of is of XX,XXX, again, map day, graph cases a But these rise less new activity corner, States. correlated new by this United of XXXX, in the of middle where thing. of early the on where don't can has they significantly around that last with with in just And many the seen have masks, reopening environment left-hand you United a On this in new see right-hand also January curve. and a now another been more reported have states the that availability. COVID-XX. hospitalizations you also This is the of the new in But represent the couple is in to the doing now recommended may day,
million hope population infected been is day, currently of vaccinated On to newly get population can that two where now, which or people see percent between the vaccinated. less the immunity, of projections lower potential right-hand is upon happen side, are, having than the could somewhere but vaccinated will currently based around you either we one to we of every XX plus herd the XX%
the may a can Now, because immunity of twist escape new have by see. into prior that by to potential some throw variants and But vaccinations is given new actually we'll wait this the and something variants infection. this
is objective first solid sales. non-COVID Our to growth in achieve
core accounted our about of underlying core COVID estimated grew XX% XX%. accomplish XX% number this year continue important for plan health So, ways. of sales. year. to in businesses non-COVID non-COVID-XX last COVID-XX this because the We our and shows on the sales after different at increases were is is of a and potential visibility to our it done, growing This business our
of rep sales. XX% we've COVID, product at our people rep XX% per expanded Prior In now quite million rep. represents of product team the eight in for that that people. First sales. no our European about of strategic is XXXX, where sales sales XX% about good in productivity we overall product represents And sales, Germany, have all, the territories X.X Germany direct significantly to seen reps productivity XX was of approximately despite with other traditional actually accounted our sales million rep partners per followed we've XXXX. by and our distributors in $X.X
that fact very a So, so already the that productive good they although is are we've dropped I bit, down sign. think, a little
back processes to to work. focus Our go second be sales will that
has of First as COVID-XX We've in-person clinical the push cytokine and in-person because of training, CytoSorb raised world our across all, therapy customers, and selling on a hyperinflammation strong and storm. activities. shows treatment medical as symposia, for of trade benefited to conferences as a in-person well marketing awareness
applications. we to Next, maximize want our existing
particularly to we conferences in complications also be XXXX. in medical of patients non-COVID able ECMO. emergency overall but as the on We leverage in and virtually. this to an our decrease as remove are has well, get but approvals major the is other the plan something injury, to the liver of as today's future, sepsis, be of occur to the the we And that will applications. a that inability a held get business. lung care rivaroxaban, year, we've in acute who applications start today, drivers then such are pancreatitis into not high-risk as sales and injury, for seen to been surgery, elsewhere to new and often as particularly States, particularly year, particularly ventilation, will strength applications some of ECMO the syndrome early these complications, effectiveness But progressed other But believe to COVID call, And hope many new subsequent and in are intervention not cardiothoracic with be others. reasons disease in a later is as But to EU not one surgeries usage just of us for the the to one last And be least, as such are also here And ticagrelor growth well decrease in and these continuing this caused and of driver we elective have ECMO. HepOnFire but talk leader were third surgery we procedures, cardiac also another as surgery. hyper to to in these around septic this many inflamed. have Last and maximize want that on critical those of least, respiratory other illnesses historically applications, we’ll CytoSorb side. post-surgical as urgent endocarditis, opportunity this have demonstrate post-operative the by distress again procedures we in that became many to believe trauma this helped after clinical And significant we momentarily a we reduction or discussing growth on of the be back that from the them, focused use has in mechanical this patients surgery, United sepsis And many did and the in applications we'll world curve where and future. surgeons, such be for well of last we might see get of because well others. as concurrent in a to as going study the shock about maximize to is one in why applications we and And workflow, other hospitals, as in lung significant our off cardiac
that, So, and clinical with to strategy, executing global prioritizing let it over the Efthymios approval update, Efthymios? and clinical particularly the to discuss the me turn U.S.
